Shares of Zealand Pharma fell up to 26% following new data showing high dropout rates due to gastrointestinal side effects in its experimental weight-loss drug survodutide. Despite meeting key study targets, 19% of patients discontinued treatment compared to 2.9% on placebo, raising doubts about the drug's commercial viability. Analysts warn that side effects like vomiting could limit its market potential against competitors. The stock has already declined nearly 50% this year amid ongoing concerns about the company's obesity drug pipeline.
ISS A/S announced ongoing transactions under its share buyback programme, repurchasing a total of 3,184,170 shares at an average price of DKK 240.09, totaling approximately DKK 764.5 million. The buyback aims to reduce share capital and fulfill oblig...
United Airlines CEO Scott Kirby stated the company is open to acquiring airport slots, gates, and other strategic assets from struggling competitors. Despite a rejected merger proposal with American Airlines earlier this year, Kirby emphasized United...
Royal Unibrew initiated a share buy-back program in February 2026, which was increased from DKK 400 million to DKK 700 million in April 2026. The program is set to run until August 14, 2026, with total repurchases not exceeding DKK 700 million. As of...
Bavarian Nordic A/S has repurchased 50,169 of its own shares at an average price of DKK 182.35 since starting its share buyback program on June 2, 2026. The program allows the company to buy back shares up to a total value of DKK 150 million by July ...
Bavarian Nordic A/S has repurchased 50,169 shares at an average price of DKK 182.35, totaling DKK 9.15 million, as part of its share buy-back program running from June 2 to July 10, 2026. This program allows the company to buy back shares up to DKK 1...
